Aardvark Therapeutics vs Artelo Biosciences
AARD and ARTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AARD and ARTL compare
Aardvark Therapeutics is the larger company, worth 15 times as much as Artelo Biosciences ($29.1M against $1.9M).
Aardvark Therapeutics scores higher on the StockData Score (6 against 2 for Artelo Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AARD | ARTL |
|---|---|---|
| Size and price | ||
| Market cap | $29.1M | $1.9M |
| Share price | $1.33 | $2.07 |
| Change, 1 year | −87.6% | −95.7% |
| Change, 5 years | – | −99.9% |
| Beta (5Y) | 2.65 | 0.21 |
| Employees | 40 | 5 |
| StockData Score | ||
| Total score | 6 (better) | 2 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.5× | 0.3× (better) |
| Profitability | ||
| Return on equity | −80.9% (better) | −404% |
| Return on invested capital | – | −398% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −83.5× |
| Current ratio | 9.11 | 10.47 (better) |
| Altman Z-score | −4.08 (better) | −16.15 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −764% |
| Shareholder yield | 0.00% (better) | −764% |
| Ownership | ||
| Held by institutions | 43.6% | 1.4% |
| Held by insiders | 41.9% | 40.9% |
| Insider net buying, 12 months | −$250K | – |
| Short interest, % of float | 8.2% | 5.0% |
Go deeper
- AARD stock overview
- AARD income statement
- AARD valuation and score
- ARTL stock overview
- ARTL income statement
- ARTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.